Insider

Mckesson Corp

MCK Health Care · 1 analysis · 3 expectations tracked

Mckesson reported $111B in revenue (+7.6% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 3 open management expectations for this company. 3 insider sales recorded. Its latest periodic filing added 37 new risk factors.

Mentioned in recent filings: Ukraine Tariffs

What changed

Company history

October 2026

MCKESSON CORP: 11 recorded developments from 4 official sources in 2026-10.

  • 2026-10-06: At the closing of the transaction, CD&R will hold a majority ownership interest, and McKesson will hold a minority ownership interest. Source
  • 2026-10-06: Option Care Health will remain a separate company led by its own management team. Source
  • 2026-10-06: This investment represents an important opportunity that aligns with McKesson’s long-term strategy to expand access and affordability to innovative therapies across the care continuum. Source
  • 2026-10-06: As a strategic investor, we look forward to bringing McKesson’s experience and expertise in specialty pharmaceuticals to support Option Care Health’s strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for s Source
  • 2026-10-06: Option Care Health will continue to operate as usual, with the same commitment to its patients, providers, employees, and partners. Source
  • 2026-10-06: Under the definitive agreement, CD&R will hold a majority interest of approximately 51% in Option Care Health and McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. Source
  • 2026-10-06: The transaction value represents a premium of approximately 37% to Option Care Health’s closing share price on October 5, 2026, the last full trading day of Option Care Health’s common stock prior to the transaction announcement. Source
  • 2026-10-06: Upon completion of the transaction, Option Care Health’s common stock will no longer be publicly listed on the Nasdaq Stock Exchange, and Option Care Health will become a privately held company. Source
  • 2026-10-15: Units to be sold: 801; aggregate market value: 797128.94 USD; units outstanding: 116590363 Source
  • 2026-10-19: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 800.491 disposed, total value 797,128.94 USD at a weighted average price of 995.8 USD; owned after the last one: 5,423.496 Source
  • 2026-10-30: The New York Stock Exchange filed a notification of removal from listing for MCKESSON CORP's 1.625% Notes due 2026. Source

August 2026

MCKESSON CORP: 3 recorded developments from 1 official source in 2026-08.

  • 2026-08-01: McKesson Corporation received a federal contract new award of $1,159,388,670.44 from the Department of Veterans Affairs for Express Report: Pharmaceutical Prime Vendor (PPV) FY2026 Aug. Source
  • 2026-08-01: The award ID for the federal contract is 36C24026K1011. Source
  • The action date for the federal contract is 2026-08-01. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$111B$103B+7.6%
Operating income quarter$1.6B$1.4B+14.0%
Net income quarter$1.2B$1.1B+9.7%
Diluted EPS quarter$10.44$8.92+17.0%
Dividends per share quarter$0.94$0.82+14.6%
Operating cash flow year to date$2.9B$1.5B+89.7%
Cash and cash equivalents balance$6.5B$4B+64.2%
Long-term debt balance$9.2B$6.5B+41.1%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

95.3Q3 '251.3%90.8Q4 '25*1.8%97.8Q1 '261.1%103Q2 '261.4%106Q3 '261.5%96.3Q4 '26*2.2%105Q1 '271.3%111Q2 '271.4%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Mckesson Corp MCK$111B+7.6%1.4%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%
Johnson & Johnson JNJ$25.4B+5.9%—

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Fiscal 2027 adjusted earnings per diluted share guidance indicates 17% to 19% growth compared to the prior year.

    Said November 4, 2026 · Period named: Fiscal 2027 · Source · Our article

    Not yet checked against later reports.

  • The Prescription Technology Solutions segment initiative is anticipated to be substantially complete by the end of fiscal 2029.

    Said November 4, 2026 · Period named: fiscal 2029 · Source · Our article

    Not yet checked against later reports.

  • McKesson raised its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00.

    Said November 4, 2026 · Period named: fiscal 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (37)

  • Additional information regarding the factors affecting our results is included in "Results Of Operations" within the consolidated discussion of Revenues.
  • Revenues | $ | 110,957 | | | $ | 103,150 | | | 8 | | % | | $ | 216,337 | | | $ | 200,977 | | | 8 | | %
  • Gross profit | 3,956 | | | 3,542 | | | 12 | | | | 7,641 | | | 6,821 | | | 12

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 30, 2026Removal of a security from listing (Form 25)25-NSE

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 5, 2026Francisco FragaSale 10b5-1 plan notice filed650$1,102.96$716,924SEC
November 4, 2026Francisco FragaSale 10b5-1 plan notice filed600$1,050.00$630,000SEC
October 15, 2026Francisco FragaSale 10b5-1 plan notice filed800$995.80$797,129SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock10,089,926$8,614,879,713-6.5%Q3 2026
State Street5,545,855$4,740,385,578-3.2%Q3 2026
Geode Capital Management2,976,448$2,532,053,133+5.5%Q3 2026
Fidelity (FMR)2,857,219$2,439,521,544+34.1%Q3 2026
Norges Bank (Norway's sovereign fund)1,529,056$1,155,354,714—Q2 2026
D. E. Shaw & Co.503,088$429,541,565+4.0%Q3 2026
Citadel Advisors217,856$186,007,631-52.7%Q3 2026
Renaissance Technologies195,166$166,634,682-46.0%Q3 2026
Millennium Management120,273$102,690,290+18.9%Q3 2026
Bridgewater Associates72,711$62,081,379+3.3%Q3 2026
Wellington Management25,413$21,697,874-47.3%Q3 2026
Two Sigma Investments922$787,213-85.7%Q3 2026
T. Rowe Price585,208$499,657-7.1%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.